N-[(3-trifluoromethylphenyl)methyl]-chloroacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(3-trifluoromethylphenyl)methyl]-chloroacetamide
• 英文别名: 2-chloro-N-[3-(trifluoromethyl)phenylmethyl]-acetamide；2-Chloro-N-(3-trifluoromethyl-benzyl)-acetamide；2-chloro-N-[[3-(trifluoromethyl)phenyl]methyl]acetamide
• 化学式: C₁₀H₉ClF₃NO
• mdl: MFCD09938871
• 分子量: 251.636
• InChiKey: AFWJINGUGZLWCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[(3-trifluoromethylphenyl)methyl]-chloroacetamide 、 Potassium;3-methyl-2-oxo-[1,2,4]triazino[2,3-c]quinazoline-6-thiolate 以 异丙醇 为溶剂， 反应 1.5h， 以59.8%的产率得到N-(3-trifluoromethylbenzyl)-2-[(3-methyl-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamide
  参考文献：
  名称：

  Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides: synthesis, cytotoxicity, anticancer activity, COMPARE analysis and docking

  摘要：

  The series of novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides were obtained by aminolysis of activated acids 1a-1d and by alkylation of potassium salts 2a-2d by N -aryl-2-chloroacetamies. The structures of compounds were determined by IR, H-1, C-13 NMR, LC- and EI-MS analyses. The results of cytotoxicity evaluation by bioluminescence inhibition of bacterium Photobacterium leiognathi Sh1 showed that compounds reveal moderate cytotoxicity. Screening of anticancer activity in vitro yielded the most active compounds 3t, 4b, 4f, 4l and 4n in micromolar concentrations with the GI(50) level (logGI(50) is from -7.57 to -4.05 for different cell lines, and logGI(50) mean graph midpoint varied from -5.30 to -4.50). Moreover, compound 4b had a distinctive selectivity against renal cancer, 4f-colon cancer and melanoma and 4l-renal cancer. The highest sensitivity to compound 4b showed renal cancer cell lines A498 (logGI(50) = -7.57). SAR-analysis was discussed, COMPARE analysis and docking was studied.The novel synthesis methods of the N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides are proposed. Anticancer activity and Photobacterium leiognathi Sh1 bioluminescence inhibition of synthesized compounds are discussed. SAR-analysis was discussed, and COMPARE analysis and docking was studied.

  DOI：

  10.1007/s00044-012-0257-x
• 作为产物：
  描述：

  3-(三氟甲基)苯甲胺 、 氯乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 N-[(3-trifluoromethylphenyl)methyl]-chloroacetamide
  参考文献：
  名称：

  骨髓嗜生态病毒整合位点 1 抑制剂的先导优化和构效关系研究

  摘要：

  我们之前的研究结果报道了骨髓嗜嗜性病毒整合位点 1 (MEIS1) 转录因子在心脏再生和造血干细胞 (HSC) 调节中的关键作用。MEIS1 作为药理抑制背景下的一个有希望的靶点，我们鉴定了一种有效的髓系亲嗜性病毒整合位点 (MEIS) 抑制剂 MEISi-1，可在体外和体内诱导小鼠和人类 HSC 扩增。在这项工作中，我们通过合成 45 种新型类似物对 MEISi-1 进行了先导优化。构效关系研究揭示了环A上的对甲氧基和环B间位的疏水部分的重要性. 获得的生物学数据得到了抑制剂对接和分子动力学模拟研究的支持。11 种化合物被描述为强效抑制剂，证明对 MEIS1 和靶基因Meis1、Hif-1 α 和p21具有更好的抑制作用。其中，4h、4f和4b是最有效的抑制剂。预测的药代动力学特性满足药物相似性标准。此外，化合物对人皮肤成纤维细胞既没有细胞毒性，也没有致突变性。

  DOI：

  10.1021/acs.jmedchem.1c00972

文献信息

• 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as
  申请人：Merck & Co., Inc.

  公开号：US04800211A1

  公开（公告）日：1989-01-24

  3-Hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by: (1) treating a substituted 2-halobenzoate with a thioacetamide. (2) treating a substituted thiosalicylate with an appropriately substituted haloacetamide; and (3) further synthetic modification of compounds prepared above. These compounds have been found to be effective inhibitors of both cyclooxygenase and lipoxygenase and thereby useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandins and/or leukotriene mediated diseases.

  3-羟基苯并[b]噻吩-2-甲酰胺衍生物已通过以下方法制备：(1)用硫代乙酰胺处理取代的2-卤代苯甲酸酯。(2)用适当取代的卤代乙酰胺处理取代的硫代水杨酸酯；以及(3)对上述制备的化合物进行进一步的合成修饰。已发现这些化合物对环氧化酶和脂氧合酶均具有有效抑制作用，因此在治疗疼痛、发热、炎症、关节炎、哮喘、过敏性疾病、皮肤病、心血管疾病、银屑病、炎症性肠病、青光眼或其他前列腺素和/或白三烯介导的疾病治疗中具有用处。
• Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors
  申请人：Meier Heinrich

  公开号：US20090312381A1

  公开（公告）日：2009-12-17

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08084481B2

  公开（公告）日：2011-12-27

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，它们的单独或组合使用用于治疗和/或预防疾病以及用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病的药物。
• SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
  申请人：Meier Heinrich

  公开号：US20130005704A1

  公开（公告）日：2013-01-03

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新型取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，其单独或联合用于治疗和/或预防疾病的用途以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• US4800211A
  申请人：——

  公开号：US4800211A

  公开（公告）日：1989-01-24